Drug Details
| General Information of the Drug (ID: DR7558) | ||||
|---|---|---|---|---|
| Name |
ONO-8711
|
|||
| Synonyms |
6-[(2R,3S)-3-(4-Chloro-2-methylphenylsulfonamidomethyl)bicyclo[2.2.2]oct-2-yl]-5(Z)-hexenoic acid
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Pain [ICD-11: MG30-MG3Z] | Terminated | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C22H30ClNO4S
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC1=C(C=CC(=C1)Cl)S(=O)(=O)NCC2C3CCC(C2C=CCCCC(=O)O)CC3
|
|||
| InChI |
1S/C22H30ClNO4S/c1-15-13-18(23)11-12-21(15)29(27,28)24-14-20-17-9-7-16(8-10-17)19(20)5-3-2-4-6-22(25)26/h3,5,11-13,16-17,19-20,24H,2,4,6-10,14H2,1H3,(H,25,26)/b5-3-/t16?,17?,19-,20-/m0/s1
|
|||
| InChIKey |
VVEXPDRCGCQELD-CFDZEDGGSA-N
|
|||
| CAS Number |
CAS 216158-34-8
|
|||
| TTD Drug ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Epigallocatechin gallate | Hamamelis virginiana | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| Up-regulation | Ratio of Bax to Bcl-2 | |||||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
ONO-8711 significantly inhibited PGE2-induced HCC proliferation while increased the inhibitory effect of EGCG on HCC cell viability and migration ability compared with EGCG alone. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Prostaglandin E2 receptor EP1 (PTGER1) | Molecule Info | [3] | |
| KEGG Pathway | Calcium signaling pathway | Click to Show/Hide | ||
| 2 | Neuroactive ligand-receptor interaction | |||
| 3 | Pathways in cancer | |||
| Panther Pathway | PI3 kinase pathway | Click to Show/Hide | ||
| Reactome | Prostanoid ligand receptors | Click to Show/Hide | ||
| 2 | G alpha (q) signalling events | |||
| WikiPathways | Prostaglandin Synthesis and Regulation | Click to Show/Hide | ||
| 2 | GPCRs, Class A Rhodopsin-like | |||
| 3 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
| 4 | Small Ligand GPCRs | |||
| 5 | GPCR ligand binding | |||
| 6 | GPCR downstream signaling | |||
